Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?

British Journal of Clinical Pharmacology

Volumn 58, Issue 3, 2004, Pages 326-328

  De Graaf, L ^a   Brouwers, A H P M ^b   Diemont, W L ^a  

^a NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

^b General Practice   (Netherlands)

Author keywords

Decreased libido; Decreased testosterone; Hydroxymethylglutaryl CoA Reductase Inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; AMOXICILLIN; ATORVASTATIN; CARBASALATE CALCIUM; CHOLESTEROL; DICLOFENAC; DILTIAZEM; DIPYRIDAMOLE; DOXYCYCLINE; FLUINDOSTATIN; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; STATIN; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIBIDO DISORDER; MALE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; LIBIDO; MALE; MIDDLE AGED; PRAVASTATIN;

EID: 4444382906     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02128.x     Document Type: Article

References (10)

1. Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 2002; 19: 95-8.
2. Crenshaw TL, Goldberg PJ. Testosterone in men. In Sexual Pharmacology, eds Crenshaw TL, Goldberg PJ. New York: WW Norton Co., 1996; 115-28.
3. Griffin JE, Wilson JD. Disorders of the testes. In Harrison's Principles of Internal Medicine, 15th edn, Braunwald, E, Fauci, AS, Kapser, DL, Hauser, SL, eds Longo DL, Jameson JL. New York: McGraw-Hill Medical Publishing Division, 2001; 2143-54.
4. Jay RH, Sturley RH, Stirling C et al. Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. Br J Clin Pharmacol 1991; 32: 417-22.
5. Ginsberg HN, Golberg IJ. Disorders of intermediary metabolism. In Harrison's Principles of Internal Medicine, 15th edn, eds Braunwald E, Fauci AS, Kapser DL, Hauser SL, Longo DL, Jameson JL. New York: McGraw-Hill Medical Publishing Division, 2001; 2245-57.
6. Azzarito C, Boiardi L, Vergoni W, Zini M, Portioli I. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm Metab Res 1996; 28: 193-8.
7. Smals AG, Weusten JJ, Benraad TJ, Kloppenborg PW. The HMG-CoA reductase-inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid- oxidoreductase enzyme activity. J Steroid Biochem Mol Biol 1991; 38: 465-8.
8. Travia D, Tosi F, Negri C, Faccini G, Moghetti P, Muggeo M. Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads. J Clin Endocrinol Metab 1995; 80: 936-40.
9. Bernini GP, Brogi G, Argenio GF, Moretti A, Salvetti A. Effects of long-term pravastatin treatment on speramtogenesis and on adrenal and testicular steroidogenesis in male hypercholesterolemic patients. J Endocrinol Invest 1998; 21: 310-7.
10. Arnaiz JA, Carné X, Riba N, Codina C, Ribas J, Trilla A. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals. Eur J Clin Pharmcacol 2001; 57: 89-91.